Literature DB >> 30175070

The role of palbociclib in thyroid carcinoma with BRAF mutation.

Nikolaos Tsoukalas1,2, Konstantinos Tsapakidis2, Krystallenia I Alexandraki3.   

Abstract

Entities:  

Year:  2018        PMID： 30175070      PMCID： PMC6107606          DOI： 10.21037/gs.2018.03.07

Source DB:  PubMed          Journal:  Gland Surg        ISSN： 2227-684X


× No keyword cloud information.
  32 in total

1.  Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes.

Authors:  A Salajegheh; R A Smith; K Kasem; V Gopalan; M R Nassiri; R William; A K Y Lam
Journal:  Eur J Surg Oncol       Date:  2010-11-18       Impact factor: 4.424

2.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

3.  GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.

Authors:  Jean-Philippe Spano; Y Vano; S Vignot; T De La Motte Rouge; L Hassani; R Mouawad; F Menegaux; D Khayat; L Leenhardt
Journal:  Med Oncol       Date:  2011-09-25       Impact factor: 3.064

4.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

Authors:  Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

Review 5.  ERK implication in cell cycle regulation.

Authors:  Jean-Claude Chambard; Renaud Lefloch; Jacques Pouysségur; Philippe Lenormand
Journal:  Biochim Biophys Acta       Date:  2006-11-17

Review 6.  Molecular genetics and diagnosis of thyroid cancer.

Authors:  Yuri E Nikiforov; Marina N Nikiforova
Journal:  Nat Rev Endocrinol       Date:  2011-08-30       Impact factor: 43.330

7.  Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.

Authors:  Keiran S M Smalley; Mercedes Lioni; Maurizia Dalla Palma; Min Xiao; Brijal Desai; Suzanne Egyhazi; Johan Hansson; Hong Wu; Alastair J King; Patricia Van Belle; David E Elder; Keith T Flaherty; Meenhard Herlyn; Katherine L Nathanson
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

8.  Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma.

Authors:  Xiao-Min Yu; Chung-Yau Lo; Alfred King-Yin Lam; Pauline Leung; John M Luk
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

9.  Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.

Authors:  Hubing Shi; Gatien Moriceau; Xiangju Kong; Mi-Kyung Lee; Hane Lee; Richard C Koya; Charles Ng; Thinle Chodon; Richard A Scolyer; Kimberly B Dahlman; Jeffrey A Sosman; Richard F Kefford; Georgina V Long; Stanley F Nelson; Antoni Ribas; Roger S Lo
Journal:  Nat Commun       Date:  2012-03-06       Impact factor: 14.919

10.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.